Massachusetts Institute of Technology
Sign in Create Account

What Can We Learn From Related Industries?

08/12/2004 3:15PM Wong Auditorium
Scott Sarazen, Senior Vice President, Life Sciences, MassDevelopment; Andrew Parece, Vice President, Analysis Group/Economics Analysis Group, Inc; Tamsin S. Randlett, Senior Director, Government Affairs, Gap Inc. ; Stephen M. Sammut, Venture Partner, Burrill & Company

Description: In some ways, the pharmaceutical industry is unique from other industries, its upfront R&D costs, for instance are extremely high. But these panelists see some commonalities with other business sectors, and offer observations and counsel to drug manufacturers. Andrew Parece focuses on the trade of high tech goods, such as software, digital cameras and DVDs. There are difficulties controlling the free flow of these goods, and their prices, across borders a challenge the drug industry also confronts today. Parece suggests that pharma companies "leverage their competitive advantage 'to differentiate products, and turn offerings into products and services such as patient assistance and education, and disease management." Tamsin Randlett of Gap, Inc. deals more with issues on the manufacturing end. The Gap outsources clothing production to companies in parts of the world where wage and labor standards lag. To respond to concerns about equity and human rights, Randlett partners with international labor organizations and NGOs. She suggests pharmaceutical industries similarly "leverage world health organizations 'to bring greater credibility to your efforts" and sit down with politicians, even those opposed to industry positions. Stephen Sammut's venture capital group invests in the biosecurity business. Just as in drug manufacturing, biosecurity involves risky and expensive R&D, licensing and liability questions, and unpredictable market size. Since "northern hemisphere concerns about biosecurity are the daily disease burden of many countries in the southern hemisphere," says Sammut, one answer to the pricing problem may be creating drugs useful for both markets simultaneously.

Host(s): Sloan School of Management, MIT Sloan School of Management

Comments (0)

It looks like no one has posted a comment yet. You can be the first!

You need to log in, in order to post comments. If you don’t have an account yet, sign up now!

MIT World — special events and lectures

MIT World — special events and lectures

Category: Events | Updated 10 months ago

Created
December 13, 2011 11:18
Category
Tags
License
All Rights Reserved (What is this?)
Additional Files


Viewed
2418 times

More from MIT World — special events and lectures

How Can We Plan for Safe and Sustainable Regions?

How Can We Plan for Safe and Sustai...

Added over 3 years ago | 02:00:00 | 3559 views

Improving Today's Energy Systems

Improving Today's Energy Systems

Added over 3 years ago | 01:27:00 | 3597 views

Environmental Impacts of Aviation

Environmental Impacts of Aviation

Added over 3 years ago | 01:02:00 | 4246 views

Rethinking Climate Change: The Past 150 Years and the Next 100 Years

Rethinking Climate Change: The Past...

Added over 3 years ago | 02:13:00 | 11541 views

Vegetation Dynamics and the Earth System

Vegetation Dynamics and the Earth S...

Added over 3 years ago | 01:06:00 | 2605 views

Philip Condit Keynote Speech

Philip Condit Keynote Speech

Added over 3 years ago | 00:38:45 | 1680 views